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ABSTRACT
Objectives: Intravesical Bacillus Calmette-Guérin (BCG) vaccine is the mainstay of treatment 
and prophylaxis in superficial bladder cancer (SBC) as it reduces tumor recurrence and disease 
progression. About one-third of patients do not respond to BCG. The aim of this study was to 
determine the efficacy of intravesical gemcitabine in patients with BCG-refractory SBC.
Methods: Twenty three patients with SBC; TaG3, T1G2-G3 or carcinoma in situ (CIS), refractory 
(after at least 2 courses of intravesical BCG) or intolerant to intravesical BCG therapy were 
included. Two weeks after complete tumor resection, patients received intravesical gemcitabine 
twice weekly at a dose of 2.000 mg/100 ml normal saline for 6 consecutive weeks. Two months 
after the last dose, recurrence-free patients underwent cystoscopy, urinary cytology and 6 random 
bladder biopsies. Thereafter, patients were evaluated by the same measures every 3 months, as 
long as there was no recurrence. Patients with complete response (negative cytology and random 
biopsies) at the first follow-up cystoscopy received a similar maintenance dose once weekly for 
another 6 weeks.
Results: Twenty one patients completed the study: 15 males and 6 females with a mean age 
of 48.1 (38-72) years. The follow-up was 15 months (range 2-19 months). Thirteen (61.9%) 
patients were recurrence-free after a mean of 17 months. Superficial recurrences were detected in 
6 (28.6%) patients and progression by stage in 2 patients (9.5%). During follow-up, 8 patients had 
tumor recurrences and 2 had progression to a higher stage. The median recurrence-free time was 
14.7 months (5-19 months). The drug was well tolerated and side-effects were mild in all patients, 
except two: one had easily controlled hematuria and the other had leucopenia. 
Conclusion: In properly selected patients, gemcitabine seems to be a promising option in the 
management of high-risk BCG-refractory SBC, especially in those who refuse or are unfit for 
cystectomy. Long-term efficacy and the role of maintenance therapy have to be properly studied.
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INTRODUCTION                                                    
Bladder cancer is a heterogeneous 
disease with a variable natural history. On 
average, 70% of bladder tumors present 
as non–muscle-invasive bladder cancer 
(NMIBC)1.  Recurrence rates after initial 
treatment range from 30% to 85%, with 
grade progression occurring in 10% to 30% 
and stage progression in 4% to 30% of cases2. 
This high rate of recurrence and progression 
can be reduced with intravesical therapy after 
proper complete transurethral resection of 
the bladder tumor (TURBT)3. Intravesical 
bacillus Calmette-Guérin (BCG) vaccine is 
the mainstay of superficial bladder cancer 
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biopsies if there was no visible recurrence. 
Thereafter, recurrence-free patients were 
evaluated by the same measures every 3 
months. Patients who revealed complete 
response after the first follow-up cystoscopy 
(in terms of negative cytology and random 
biopsies) received a maintenance similar 
dose once weekly for another 6 consecutive 
weeks. The following variables were 
recorded for every patient: age and sex, 
previous intravesical therapy with response 
and tolerance, pathological stage before start 
of gemcitabine therapy, cystoscopy status and 
date, response to intravesical gemcitabine, 
time of recurrence and/or progression and 
toxicity of the drug. Complete response (CR) 
was defined as absence of suspicious lesions 
on cystoscopy and/or negative biopsies and 
cytology. Recurrence-free survival time is 
the time from the date of response to therapy 
to the date of recurrence or last follow-
up. Time to progression is from the date of 
response to therapy to the date of progression 
or cystectomy.
RESULTS                                                            
Twenty one patients completed the study: 
15 males and 6 females with a mean age 
of 48.1 (38-72) years. Two patients were 
lost to follow-up early during induction 
therapy. The median duration of follow-up 
was 15 months (ranging from 2-19 months). 
Patient data are shown in Table 1. Thirteen 
(61.9%) patients had T1G2-3 TCC ± CIS, 
5 (23.8%) patients had CIS and 3 (14.3%) 
patients had high grade Ta TCC. The efficacy 
of intravesical gemcitabine is shown in 
Table 2. During  follow-up 8 patients 
had  tumor recurrence and 2 of them had 
progression to a higher stage. Figure 1 shows 
the response to gemcitabine as regards 
pathological stage and grade during follow-
up. The superficial recurrences occurred 
early (after 2 months in 2 patients) which 
represents non-response to gemcitabine. 
Other recurrences were detected at 5 months 
in one patient, 14 months in 2 patients, and 
17 months in one patient. Two patients in this 
category underwent radical cystectomy and 
(SBC) treatment in terms of reduction of 
tumor recurrence and disease progression4. 
Unfortunately, about one-third of patients 
do not respond to BCG, which represents 
a significant challenge5. Gemcitabine is an 
active systemic chemotherapeutic agent 
in the management of advanced bladder 
cancer and it has also been evaluated in the 
management of superficial disease. The aim 
of this study was to determine the efficacy 
of gemcitabine hydrochloride administered 
as intravesical agent in patients with BCG-
refractory/intolerant SBC.
PATIENTS AND METHODS                                     
Twenty three patients were included 
in the study after fulfilling the inclusion 
criteria. Informed consent was signed by all 
patients after being informed about the study, 
different management options, the possibility 
of response, and the side-effects of the drug. 
The inclusion criteria were: (1) histologically 
proven recurrent superficial transitional cell 
carcinoma (TCC) of the bladder (TaG3, 
T1G2-3, or CIS); (2) at least two previous 
courses of failed intravesical BCG (or 
intolerance to intravesical BCG therapy) 
± one course of chemotherapy other than 
gemcitabine; (3) no previous gemcitabine 
therapy; (4). no other malignancy apart from 
the existing bladder tumor; (5) Females must 
neither be pregnant nor lactating. Two weeks 
after TURBT, patients received intravesical 
gemcitabine twice weekly at a dose of 2.000 
mg/100 ml normal saline for 6 consecutive 
weeks. Gemcitabine was instilled via a Foley 
transurethral catheter and remained in the 
bladder for 2 hours. Patients were advised 
to change their position in bed from time 
to time. Complete emptying of bladder was 
done routinely prior to therapy in order 
to improve therapeutic efficacy. Patients 
were asked to restrict fluid intake and to 
take systemic alkalinizer one day before 
therapy for better absorption of gemcitabine. 
Blood tests (complete blood count (CBC), 
liver enzymes, and serum creatinine) were 
performed before gemcitabine therapy and 
before each cystoscopy. Two months after 
the last dose, patients underwent cystoscopy, 
urinary cytology and 6 random bladder 
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the other 4 were followed up with cystoscopy. 
Stage progression was detected in 2 patients, 
at 8 and 11 months after starting intravesical 
therapy. Both patients progressed to muscle 
invasive disease; one underwent radical 
cystectomy, the other was unfit for surgery 
and died 2 months later. Complete response 
was present in 13 (61.9%) patients up to 19 
months of follow-up. 
The median recurrence-free time was 
14.7 months (5 to 19 months). The drug was 
tolerable and side-effects were mild in most 
patients, apart from two patients; one had 
easily controlled hematuria and the other 
had leucopenia. Four patients developed 
cystitis syndrome, but their symptoms 
were easily controlled and did not affect 
treatment strategy.
DISCUSSION                                                             
Treatment of SBC aims to eradicate 
existing disease and to prevent tumor 
recurrence and/or progression to muscle 
invasion and metastasis. Patients treated only 
by TURBT have a 49% chance of remaining 
free of disease6. Intravesical chemotherapy 
and immunotherapy have resulted in 
significant reduction in the risk of disease 
recurrence. SBC lends itself to intravesical 
therapy due to the potential for direct contact 
between chemotherapeutic drug and tumor. 
Furthermore, very high concentrations of 
agents can be achieved in the bladder with 
minimal systemic toxicity7. BCG 
immunotherapy has become the standard 
treatment for high-risk SBC, including T1G3, 
CIS and some recurrent Ta cases4. However, 
BCG treatment fails in 30-40% of patients, 
and 30-40% of those who initially respond, 
eventually relapse8. Peyromaure and 
coworkers reported 42% and 28% recurrence 
and progression rates, respectively, in 57 
patients followed up for 53 months9. Shahin 
and associates found that 70% of their 
patients recurred after BCG, versus 75% 
treated with TURBT alone10. These results 
have led many authors to advocate early 
cystectomy for T1G3 SBC, particularly in 
the presence of unfavorable prognostic 
factors11. Hence, BCG is not always effective 
and response is not always durable. Failure 
to achieve a complete response following 
BCG induction predicts poor prognosis, 
including a 67% higher risk of death. Risk 
factors reported for non-response, recurrence 
or progression include increased numbers of 
tumors, large tumor size, older age, prior 
recurrence, more advanced stage or grade, 
and the presence of CIS. Radical cystectomy 
can be the first treatment of choice for young, 
otherwise healthy patients with high-grade 
T1 disease, or patients with multifocal CIS 
who cannot tolerate BCG. The 5-year 
disease-free survival rate with radical 
cystectomy is approximately 85% for patients 
with pathologic node-negative T1 tumors 
(pT1) and 95% for stage pTa or pCIS tumors, 
making radical cystectomy an excellent 
initial treatment for selected high-risk 
patients12. the significant limitations in 
efficacy and tolerability for the most widely 
used intravesical drugs across all risk 
categories of SBC have favored the search 
for new treatment alternatives4. In the past 
few years, new drugs have been investigated 
that may play a future role in this indication13. 
Table 1: Pre-gemcitabine pathologic stage and grade of the 
study patients.
Stage No   (%)
TaG3 3    (14.3)
T1 G2
T1 G3
4    (19.0)
9    (42.9)
CIS 5    (23.8)
Total 21   (100)
Table 2: Efficacy of intravesical gemcitabine in the study 
patients.
Results No   (%)
Recurrence-free 13   (61.9)
Superficial recurrence 6   (28.6)
Progression  2   (9.5)
Total  21   (100)
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This study evaluated the efficacy of 
intravesical gemcitabine as a 
chemotherapeutic agent in patients 
with BCG-refractory SBC. Systemic 
chemotherapy with gemcitabine and cisplatin 
for locally advanced muscle-invasive bladder 
cancer has shown promising results14,15 with 
low side-effects and good tolerability as an 
alternative treatment option to conventional 
radical cystectomy. Gemcitabine, a deoxy-
cytidine analogue, has a broad-spectrum anti-
tumor activity. Being a non-vesicant drug, it 
has very little local toxicity, therefore a high 
concentration in the bladder can be achieved 
without drug-induced cystitis. It penetrates 
the bladder mucosa well, due to its low 
molecular weight of 299 Da and 
preferentially produces cytotoxicity in 
bladder cancer cells while sparing non-
transferred bladder mucosa and submucosal 
cells. Its rapid transformation into an inactive 
metabolite prevents systemic toxicity5. No 
systemic absorption with a clinical or 
pharmacological effect was detected and 
only slight irritative bladder symptoms were 
observed16. Intravesical gemcitabine has 
shown an excellent safety profile with 
minimal toxicity at concentrations up to 40 
mg/ml and this should therefore be the 
standard dose for any future study4. 
Instillation times of one and two hours have 
both been tested with excellent tolerability17. 
However, instillation over 2 hours seems to 
be a feasible option and might be better than 
instillation for 1 hour4. In this study the 
recommended dose and instillation time had 
been planned. Table 3 shows some studies 
investigating the activity of intravesical 
gemcitabine in intermediate and high-risk 
SBC. It has to be mentioned that comparison 
between the results of those studies could not 
be done because they have different 
methodologies as regards patients’ data, the 
dose and schedule of drug administration, 
and the planning of maintenance therapy. In 
the phase II study of Dalbagni and colleagues, 
Authors No Pts Schedule MFUmonth RF SR Prog.
Dalbagni et al24 18 Twice weekly for 3 wks, repeated after a week of rest 2 7 4 PR NS
Montella et al20 9 4 wks before and 4 wks after TURBT 17 2 7 0
Bounedjar et al22 118 6 wks induction + Maint. 3 weekly at 3, 6, 12, 18, 24, 30, 36 months 12 85 29 NS
Gontero et al17 30 Twice weekly for 3 wks, repeated after a week of rest 19 2
12
(+7 PR) 1
Dalbagni et al18 9 NS 21 3 6 0
Gunelli et al25 40 Twice weekly/ 6wks 28 14 14 0
Bounedjar et al26 60 Once weekly / 6wks+ Monthly/ 6 months 39 53 5 2
Gontero et al4 35 Once weekly / 6wks 18 21 11 3
Gacci et al19 48 Once weekly / 6wks NS 42 0 6
Mattioli et al21 60 6 wks induction + monthly dose/ 6 months 60 23 26 6
Table 3: Studies of intravesical gemcitabine in intermediate and high risk SBC.
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30 eligible patients were included with a 
median follow-up of 19 months (range, 0 to 
35 months). Of the 30 patients, 15 achieved 
CR, of whom only 2 patients maintained CR 
at 23 and 29 months, respectively18. These 
differences from our results could be related 
to two main causes; firstly, differences in the 
primary grade and stage of the SBC (23/30 
patients were CIS). Secondly, the difference 
in methodology, as the patients in the phase 
II study received only two courses of 
intravesical gemcitabine twice weekly for 3 
consecutive weeks, with each course 
separated by one week of rest without 
maintenance. The role of maintenance 
therapy should be investigated in future 
studies. Mohanty et al reported that 21 (60%) 
patients showed no recurrences, 11 (31.4%) 
had superficial recurrences while 3 (8.6%) 
progressed to muscle invasiveness5. Average 
time to first recurrence was 12 months and to 
disease progression was 16 months5. No 
maintenance therapy was planned in that 
study and the higher response rate was due 
to 18 (50%) of patients with low grade Ta 
TCC. Gacci and others confirmed the high 
risk of tumor recurrence and progression of 
BCG-refractory pT1G3 TCC and 
recommended that further BCG courses seem 
to be unsuitable, resulting in a high risk of 
tumor progression and mortality19. Of the 9 
patients treated with gemcitabine, 3 were 
recurrence-free after 13, 17 and 21 months. 
The authors concluded that the use of 
gemcitabine in BCG-refractory pT1G3 
patients has to be considered experimental 
until multicentre randomized studies with 
adequate follow-up are able to confirm their 
preliminary results19. The low response rate 
to gemcitabine in that series may be the 
result of the smaller sample size and the fact 
that all patients had stage pT1G3 tumours. In 
our study and that of Mohanty and 
colleagues5, there were some patients who 
had pTaG3 and pT1G2 whose response to 
gemcitabine might have been much better. 
Montella and others studied intravesical 
gemcitabine versus mitomycin-C (MMC) for 
recurrent SBC. In the gemcitabine group 42 
(78%) patients remained free of recurrence 
compared to 37 (67%) patients in the MMC 
group (p=0.05). Ten patients in the MMC 
Fig. 1: Response of the patients to intravesical gemcitabine over months as regard to the pathological stage and grade.
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arm and 6 in the gemcitabine group had 
progressive disease by stage. The authors 
concluded that intravesical therapy with 
gemcitabine is active and better tolerated 
than MMC in refractory TCC patients20. The 
higher rate of response to gemcitabine in the 
previous series over all other published data 
was because all patients had low-grade, low-
stage disease (Ta-T1G1-G2). In the series of 
Mattioli and associates, one patient had 
recurrence 1 month after TURBT, 3 patients 
between 3 and 6 months, and another 3 after 
8, 11 and 18 months and 2 were recurrence-
free after 21 and 22 months, respectively21. 
Their results could not be compared to that 
of the present study as their sample was 
relatively small (9 patients). Also, the 
authors’ methodology was different in that 
gemcitabine was administered once a week 
in the 4 weeks before and the 4 weeks after 
TURBT. Moreover, the pathologic stages and 
grades of their patients were not presented. 
Smaili and colleagues presented the results 
at 5 years of intravesical gemcitabine single 
agent as adjuvant chemotherapy in superficial 
TCC of the bladder22. Sixty patients (9 had 
CIS and 51 had pT1) received intravesical 
instillation of gemcitabine once weekly for 6 
weeks, then every month for 6 months. They 
found that 23 (38.3%) patients had 
a persistent CR after treatment, 26 (43.3%) 
had superficial relapse of TCC, and 6 (10%) 
had progressive disease22. The authors used a 
different and unique protocol for maintenance 
therapy. Bartoletti and colleagues performed 
a multicentric study of 118 patients followed 
for a mean of 12 months; 85 (74.6%) 
were recurrence-free and 29 (25.4%) 
showed superficial  recurrences23. Intravesical 
gemcitabine is well tolerated, associated with 
minimal systemic absorption and has a 
moderate efficacy in the treatment of 
SBC17-20. In this study, intravesical 
gemcitabine was well tolerated with mild 
side-effects in most patients. One patient had 
easily controlled hematuria, another one had 
leucopenia. Four patients developed cystitis 
syndrome, but their symptoms were easily 
controlled and did not affect treatment 
strategy. Gemcitabine has low and transient 
adverse events and excellent cytotoxic effect 
with the result that more intense treatment 
schedules are now being contemplated. The 
ongoing phase II studies would provide 
additional information to predict the efficacy 
of gemcitabine in clinical practice and 
constitute the framework for large 
comparative phase III studies.
Conclusions 
Gemcitabine appears to be a promising 
option in management of high-risk patients 
with BCG-refractory SBC especially those 
who refuse or unfit for cystectomy. Long-
term efficacy and the role of maintenance 
therapy have to be properly investigated. 
The question now not about the efficacy of 
the drug but which group of patients could be 
selected for this treatment strategy?
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